Table S1, Table S2 from Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Autor: Ulrik N. Lassen, Martin Weisser, Birgit Bossenmaier, Francesca Michielin, Celine Adessi, Lori Steiner, Maitram Nguyen, Rajiv Dua, Suzana Vega-Harring, Ian James, Georgina Meneses-Lorente, Maurizio Ceppi, Marlene Thomas, Sabine Wilson, Jan H.M. Schellens, Sang-We Kim, Enriqueta Felip, Antonio Calles, Ji-Youn Han, Stefan Sleijfer, Maja J. De Jonge, Marlies H.G. Langenberg, Martijn P. Lolkema, Andres Cervantes, Tania Fleitas, Alvaro Taus, Maria Martinez-Garcia, Morten Mau-Sorensen, Emile E. Voest, Wolfgang Jacob, Didier Meulendijks

Supplementary Table 1 Downregulation of HER3 membrane protein expression in skin biopsies following treatment with lumretuzumab and cetuximab or erlotinib Supplementary Table 2 Change of tumor biomarkers in tumor biopsies following treatment with lum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::804d643b37a2cdf6fd277ce1fd5c048c
https://doi.org/10.1158/1078-0432.22468827

Supplemental table 1 from A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

Autor: Guido Tricot, Martine Poelman, Magnus Korsgren, Björn Frendeus, Maurizio Zangari, Stina Wichert, Jan Van Droogenbroeck, Ingrid Teige, Annika Sundberg, Yvonne Stenberg, Morten Mau-Sorensen, Elisabeth Sonesson, Morten Salomo, Fritz Offner, Hareth Nahi, Titti Martinsson Niskanen, Ashraf Badros, Peter Gimsing, Markus Hansson

Supplemental table 1. Bone marrow BI-505 concentration and MM-cell ICAM-1 expression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a13375faa4934a754b2d055a8470def8
https://doi.org/10.1158/1078-0432.22461654

Data from A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

Autor: Guido Tricot, Martine Poelman, Magnus Korsgren, Björn Frendeus, Maurizio Zangari, Stina Wichert, Jan Van Droogenbroeck, Ingrid Teige, Annika Sundberg, Yvonne Stenberg, Morten Mau-Sorensen, Elisabeth Sonesson, Morten Salomo, Fritz Offner, Hareth Nahi, Titti Martinsson Niskanen, Ashraf Badros, Peter Gimsing, Markus Hansson

Purpose: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of BI-505, a human anti-ICAM-1 monoclonal antibody, in advanced relapsed/refractory multiple myeloma patients.Experimental Design:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9060671db8c498c0987a1831cf0d2591
https://doi.org/10.1158/1078-0432.c.6524847

Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours

Autor: Xinhui Chen, Nicolas Isambert, Rafael López‐López, Monica Giovannini, Nathalie Pognan, Shruti Kapoor, Michelle Quinlan, Benoit You, Xiaoming Cui, Gholamreza Rahmanzadeh, Morten Mau‐Sorensen

Publikováno v: Chen, X, Isambert, N, López-López, R, Giovannini, M, Pognan, N, Kapoor, S, Quinlan, M, You, B, Cui, X, Rahmanzadeh, G & Mau-Sorensen, M 2023, ' Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours ', British Journal of Clinical Pharmacology, vol. 89, no. 3, pp. 1046-1055 . https://doi.org/10.1111/bcp.15544

Background: Preclinical studies showed that capmatinib reversibly inhibits cytochrome P450 (CYP) 3A4 and CYP1A2 in a time-dependent manner. In this study, we evaluated the effect of capmatinib on the exposure of sensitive substrates of CYP3A (midazol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e751618123039bf7c0a8151dbb589a3e
https://curis.ku.dk/portal/da/publications/effect-of-capmatinib-on-the-pharmacokinetics-of-substrates-of-cyp3a-midazolam-and-cyp1a2-caffeine-in-patients-with-metdysregulated-solid-tumours(72512f3f-33d1-4b5e-974b-4b8e0ef1d394).html

Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)

Autor: Theodore W. Laetsch, Shivaani Kummar, Steve Smith, Michael Natheson, Alan L. Ho, Anna F. Farago, Lucy Song, Birgit Geoerger, Elena Garralda, Michael Capra, Matthew H. Taylor, Mette Jorgensen, Xin Huang, Nora Ku, Ramamoorthy Nagasubramanian, Alexander Drilon, Brian B. Tuch, Neerav Shukla, Morten Mau-Sorensen, David S. Hong, David M. Hyman

Publikováno v: Cancer Research. 79:CT127-CT127

Background: Larotrectinib, a selective TRKi, is now FDA approved for pediatric and adult TRK-fusion solid tumors, regardless of tumor origin. Emergent TRK kinase mutations are a common mechanism of resistance to TRKis. LOXO-195, a selective TRKi, was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c5a7963dda0c86b58f18d39076c12503
https://doi.org/10.1158/1538-7445.am2019-ct127